ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Core Insights - ZyVersa Therapeutics, Inc. is developing Inflammasome ASC Inhibitor IC 100 to address stroke-related cardiovascular injury and dysfunction, particularly in patients with obesity [2][3][9] - The company aims to progress IC 100 into phase 1 clinical trials around mid-2025, highlighting its potential to control inflammation linked to stroke-related cardiovascular issues [3][9] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a significant market opportunity exceeding $100 billion [9] - The lead indication for IC 100 is obesity and its associated metabolic complications, while another product, VAR 200, targets focal segmental glomerulosclerosis (FSGS) [9] Research Findings - Recent studies indicate that stroke induces a catecholamine surge leading to AIM2 inflammasome activation and pyroptosis in the heart, which can be inhibited by IC 100 [5][6] - Treatment with IC 100 significantly reduced inflammasome proteins and IL-1β levels in the heart, thereby decreasing cardiac inflammation [5][6] - The research was published in the peer-reviewed journal, Translational Stroke Research, and involved studies conducted in mouse models and zebrafish hearts [4][5] Mechanism of Action - IC 100 is a humanized IgG4 monoclonal antibody designed to inhibit the inflammasome adaptor protein ASC, targeting multiple inflammasomes including AIM2 [7][8] - By binding to ASC, IC 100 prevents the formation of inflammasomes and blocks the activation of IL-1β, which is crucial in the inflammatory response [7][8]